Retroperitoneal neuroglial heterotopia: a case report and literature review.

Background: Neuroglial heterotopia is a rare lesion composed of differentiated neuroectodermal cells that manifest in extracranial locations, with the majority of cases predominantly occurring in the head and neck region. Retroperitoneal neuroglial heterotopia is exceptionally rare, with isolated cases published in the scientific literature. Case report: Here, we present the case of a 3-year-old girl who was admitted without clinical signs but presented with a palpable abdominal mass. Ultrasonography and computed tomography scans revealed a sizable cystic lesion within the retroperitoneal space. Subsequently, laparoscopic resection was performed. Histological examination unveiled neuroglial cell-lined cysts encompassing fibrous connective tissue, ganglia, glial tissue, and nerve bundles. Notably, distinct areas and cell types exhibited expression of S100, glial fibrillary acidic protein, and neuron-specific enolase. Follow-up assessments revealed no relapses or late complications. Conclusion: In cases of retroperitoneal neuroglial heterotopia, most children may remain asymptomatic without any congenital anomalies. Despite their detectability through imaging, accurate preoperative diagnosis is seldom achieved. Generally, a favorable prognosis follows complete surgical resection, although further cases are required to confirm its long-term efficacy, necessitating extended follow-up for verification.

Design, Synthesis, and Anti-Breast Cancer Activity of Novel Fluorinated 7-O-Modified Genistein Derivatives.

BACKGROUND: Genistein has been limited in clinical application due to its low bioavailability, extremely poor liposolubility, and fast glycosylation rate, though it possesses anti-breast cancer activity. Therefore, the discovery of novel genistein derivatives is an urgency. OBJECTIVE: To enhance the anti-breast cancer activity of genistein, a series of novel fluorinated genistein derivatives were synthesized. METHODS: Their in vitro antitumor activity was investigated by the MTT assay against three cancer cell lines, via, MDA-MB-231, MCF-7, and MDA-MB-435, respectively. RESULTS: Analogs 1d, 2b, and 3b showed remarkable anticancer activities compared to tamoxifen, a clinical anti-breast cancer drug on the market. CONCLUSION: The activities against breast cancer of genistein were enhanced by introducing the 7- alkoxyl group and fluorine atom into the B-ring. Therefore, these compounds may be potential candidates for treating breast cancer.

Reduction in hippocampal volumes subsequent to heavy cannabis use: a 3-year longitudinal study.

Cannabis exposure is related to neuroanatomical changes in brain regions rich in cannabinoid receptors, such as the hippocampus. However, researchers have not clearly determined whether persistent heavy cannabis use leads to morphological changes in the hippocampus or whether an earlier age of onset of first cannabis use and/or higher doses of cannabis exposure exacerbate these alterations. In this longitudinal study, we investigated whether continued heavy cannabis use in young adults is associated with an altered hippocampal volume. Twenty heavy cannabis users (CBs) and 22 healthy controls (HCs) underwent a comprehensive psychological assessment and a T1 structural scan at baseline and at a 3-year follow-up visit. Volumes of the hippocampus and its subregions were estimated using volBrain software. Except for the cornu ammonis 2 (CA2)/CA3 subregions, age had significant effects on all hippocampal subregions in both the CB and HC groups. The relative right hippocampal volume and absolute and relative right CA1 volumes displayed a greater rate of decrease in CBs compared to HCs. In addition, we explored the relationship between alterations in hippocampal volume and cannabis use characteristics. Changes in the relative right hippocampal volume and the relative right CA1 volume were related to age at first cannabis use but not to age at onset of frequent cannabis use. Alterations in the relative right hippocampal volume and absolute and relative right CA1 volumes were associated with Cannabis Use Disorder Identification Test (CUDIT) scores. Based on these results, heavy cannabis use in early adulthood is a risk factor for a greater rate of decrease in the volume of the right hippocampus (particularly the right CA1).

Cerebellar thickness changes associated with heavy cannabis use: A 3-year longitudinal study.

Cannabis is the most frequently used illicit drug in the world. Cross-sectional neuroimaging studies have revealed that chronic cannabis exposure and the development of cannabis use disorders may affect cerebllar morphology. However, cross-sectional studies cannot make a conclusive distinction between causes and consequences, and there is a lack of longitudinal neuroimaging studies. In the current study, we used longitudinal neuroimaging data to explore whether persistent cannabis use and higher levels of cannabis exposure in young adults are related to cerebellar thickness alterations. Twenty heavy cannabis users (CBs) and 22 non-cannabis-using controls (HCs) completed a comprehensive psychological assessment and a T1-structural MRI scan at baseline and a 3-year follow-up. Except for lobuleVIIB, all cerebellar subregions showed significant effects of age in both the CB and HC groups. Both VI and CrusI had higher rates of increase in CBs than in HCs. In addition, we examined the relationship between changes in cerebellar thickness and cannabis use characteristics. We found that alterations in lobule VI and CrusI were related to the age at onset first cannabis use but not the age at onset frequent cannabis use. The changes in lobule VI and CrusI were associated with the CUDIT score, even when controlling for the AUDIT score. The results indicated that an increased rate of cerebellar thickness is a risk factor for heavy cannabis use in early adulthood. Cannabis use affects the cerebellar structure, and monitoring cerebellar structural alterations that could be used as biomarkers may help guide the development of clinical tools.

Suppressive effects of 17beta-estradiol on hepatic fibrosis in CCl4-induced rat model.

AIM: To investigate the pathway via which 17beta-estradiol (beta-Est) exerts suppressive effects on rat hepatic fibrosis. METHODS: In vivo study was done in CCl4-induced female hepatofibrotic rats. Fibrosis-suppressive effect of beta-Est (20 microg/kg/d) was evaluated in intact and ovariectomized rat models. Six weeks after the treatment, all the rats were sacrificed and specimens of serum or liver tissue were collected for the studies. Serum liver enzymes, fibrosis markers and estradiol levels were determined by standard enzymatic methods, ELISA and RIA, respectively. Degrees of fibrosis and areas of hepatic stellate cells (HSCs) positive for alpha-smooth muscle actin (alpha-SMA) in the liver were determined by van Gieson (VG) stain and immunohistochemistry. In vitro studies, HSCs were isolated by a combination of pronase-collagenase perfusion and density gradient centrifugation. First-passage HSCs were randomly divided into 10 groups, and different concentrations of beta-Est, 2-hydroxyestradiol (2OHE) or 2-methoxyestradiol (2MeOE) were separately added to the cell groups. After incubation for 72 h, the degree of cell proliferation, collagen production, alpha-SMA or estrogen receptor (ER) expression was determined by MTT assay, ELISA and immunohistochemistry, respectively. RESULTS: Beta-Est treatment reduced aspartate aminotransferase (AST), alanine aminotransferase (ALT), hyaluronic acid (HA) and type IV collagen (C IV) in sera, suppressed hepatic collagen content, decreased the areas of HSCs positive for alpha-SMA significantly in both intact and ovariectomized female hepatofibrotic rats. There was a negative correlation between the percentage of fibrotic area of liver tissue and the serum estradiol level; the calculated correlation coefficient was -0.57 (P<0.01). Beta-Est and its metabolites concentration-dependently (10(-9) mol/L-10(-7) mol/L) inhibited HSC proliferation and collagen synthesis. At the concentration of 10(-7) mol/L, they could inhibit alpha-SMA expression. The order of potency was 2MeOE>2OHE>beta-Est. CONCLUSION: Beta-Est may suppress hepatic fibrosis probably via its biologically active metabolites.

[Expression of activins, follistatin mRNA in the development of hepatic fibrosis].

OBJECTIVE: To examine the expression changes of activin beta A, beta C, beta E and follistatin mRNA in the development of rat hepatic fibrosis induced by carbon tetrachloride (CCl(4)). METHODS: Hepatic fibrosis was induced in rats by subcutaneous injections of 40% carbon tetrachloride oily solution for a period of 1 to 7 weeks. After carbon tetrachloride injection of 1, 2, 3, 4, 5, 6, and 7 weeks, the 6-12 rats were killed every time. The kinetics of activin beta A, beta C, beta E and follistatin mRNA expression were assessed by the semi-quantity RT-PCR. RESULTS: Activin beta A, beta C, beta E and follistatin mRNA could be detected in normal rat livers. After CCl(4) injection for 2 or 3 weeks, beta A mRNA was transiently decreased and became undetectable, then increased gradually. After CCl injection for 6 and 7 weeks, beta A mRNA level was significantly higher than controls (P<0.01). beta C mRNA could be detected after CCl(4) injection for 1 to 4 weeks and was significantly increased after 5 weeks over controls (P<0.05). beta E mRNA could not be detected after CCl(4) injection for 1 to 5 weeks, but significantly increased after CCl(4) injection for 6 or 7 weeks compared with controls (P<0.01). Except for normal rat liver, no follistatin mRNA was detected in rats after CCl(4) injection. CONCLUSIONS: Activins and follistatin have different expression changes in the development of hepatic fibrosis and the imbalance of activins and follistatin expression may involve in the formation of hepatic fibrosis.